01093 PE Ratio & Valuation,Is 01093 Overvalued — Intellectia
01093 Relative Valuation
01093's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, 01093 is overvalued; if below, it's undervalued.
Historical Valuation
CSPC PHARMA(01093) is now in theFairzone, suggesting that its currentforward PEratio of15.24is consideredFairlycompared with the five-year average of13.97.The fair price ofCSPC PHARMA(01093)is between--to--according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：8.01
Fair
15.24
PE
1Y
3Y
5Y
Trailing
Forward
8.95
EV/EBITDA
CSPC PHARMA. (01093) has a current EV/EBITDA of 8.95. The 5-year average EV/EBITDA is 8.63. The thresholds are as follows: Strongly Undervalued below 4.03, Undervalued between 4.03 and 6.33, Fairly Valued between 10.93 and 6.33, Overvalued between 10.93 and 13.23, and Strongly Overvalued above 13.23. The current Forward EV/EBITDA of 8.95 falls within the Historic Trend Line -Fairly Valued range.
10.79
EV/EBIT
CSPC PHARMA. (01093) has a current EV/EBIT of 10.79. The 5-year average EV/EBIT is 9.28. The thresholds are as follows: Strongly Undervalued below 4.74, Undervalued between 4.74 and 7.01, Fairly Valued between 11.54 and 7.01, Overvalued between 11.54 and 13.81, and Strongly Overvalued above 13.81. The current Forward EV/EBIT of 10.79 falls within the Historic Trend Line -Fairly Valued range.
2.49
PS
CSPC PHARMA. (01093) has a current PS of 2.49. The 5-year average PS is 2.37. The thresholds are as follows: Strongly Undervalued below 1.27, Undervalued between 1.27 and 1.82, Fairly Valued between 2.92 and 1.82, Overvalued between 2.92 and 3.47, and Strongly Overvalued above 3.47. The current Forward PS of 2.49 falls within the Historic Trend Line -Fairly Valued range.
11.85
P/OCF
CSPC PHARMA. (01093) has a current P/OCF of 11.85. The 5-year average P/OCF is 11.71. The thresholds are as follows: Strongly Undervalued below 5.57, Undervalued between 5.57 and 8.64, Fairly Valued between 14.79 and 8.64, Overvalued between 14.79 and 17.86, and Strongly Overvalued above 17.86. The current Forward P/OCF of 11.85 falls within the Historic Trend Line -Fairly Valued range.
14.98
P/FCF
CSPC PHARMA. (01093) has a current P/FCF of 14.98. The 5-year average P/FCF is 16.02. The thresholds are as follows: Strongly Undervalued below 8.32, Undervalued between 8.32 and 12.17, Fairly Valued between 19.88 and 12.17, Overvalued between 19.88 and 23.73, and Strongly Overvalued above 23.73. The current Forward P/FCF of 14.98 falls within the Historic Trend Line -Fairly Valued range.
CSPC PHARMA (01093) has a current Price-to-Book (P/B) ratio of 2.34. Compared to its 3-year average P/B ratio of 2.04 , the current P/B ratio is approximately 14.75% higher. Relative to its 5-year average P/B ratio of 2.33, the current P/B ratio is about 0.41% higher. CSPC PHARMA (01093) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 2.18%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 2.39% , the current FCF yield is about -100.00% lower.
2.34
P/B
Median3y
2.04
Median5y
2.33
0.00
FCF Yield
Median3y
2.18
Median5y
2.39
Performance Decomposition
1Y
3Y
5Y
Market capitalization of 01093 increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of 01093 in the past 1 year is driven by Unknown.
Is CSPC PHARMA (01093) currently overvalued or undervalued?
CSPC PHARMA(01093)is now in theFairzone, suggesting that its currentforward PEratio of 15.24is consideredFairlycompared with the five-year average of13.97.The fair price of CSPC PHARMA(01093)is betweentoaccording to relative valuation methord.
What is CSPC PHARMA (01093) fair value?
01093's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of CSPC PHARMA (01093) is between to according to relative valuation methord.
How does 01093's valuation metrics compare to the industry average?
The average P/S ratio for 01093's competitors is , providing a benchmark for relative valuation. CSPC PHARMA Corp (01093) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for CSPC PHARMA (01093) as of Dec 18 2025?
As of Dec 18 2025, CSPC PHARMA (01093) has a P/B ratio of 2.34. This indicates that the market values 01093 at 2.34 times its book value.
What is the current FCF Yield for CSPC PHARMA (01093) as of Dec 18 2025?
As of Dec 18 2025, CSPC PHARMA (01093) has a FCF Yield of 0.00%. This means that for every dollar of CSPC PHARMA’s market capitalization, the company generates 0.00 cents in free cash flow.
What is the current Forward P/E ratio for CSPC PHARMA (01093) as of Dec 18 2025?
As of Dec 18 2025, CSPC PHARMA (01093) has a Forward P/E ratio of 15.24. This means the market is willing to pay $15.24 for every dollar of CSPC PHARMA’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for CSPC PHARMA (01093) as of Dec 18 2025?
As of Dec 18 2025, CSPC PHARMA (01093) has a Forward P/S ratio of 0.00. This means the market is valuing 01093 at $0.00 for every dollar of expected revenue over the next 12 months.
